Loading...
XNASANGO
Market cap353mUSD
Dec 24, Last price  
9.01USD
1D
-1.92%
1Q
17.43%
Jan 2017
-48.49%
Name

AngioDynamics Inc

Chart & Performance

D1W1MN
XNAS:ANGO chart
P/E
P/S
1.20
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
1.40%
Rev. gr., 5y
-3.30%
Revenues
304m
-10.28%
60,289,00078,451,000112,227,000166,500,000195,054,000216,035,000215,957,000221,787,000342,026,000354,455,000356,974,000353,690,000349,643,000344,285,000359,484,000264,157,000291,010,000316,219,000338,752,000303,914,000
Net income
-184m
L+251.53%
4,548,0006,866,000-9,127,00010,889,0009,932,00012,312,0008,226,000-5,094,000-614,0003,088,000-3,268,000-44,451,0007,008,00016,335,00061,340,000-165,787,000-31,548,000-26,547,000-52,442,000-184,349,000
CFO
-28m
L
4,788,0003,219,0008,784,00025,907,00019,942,00039,959,00033,870,00010,829,00026,294,00025,284,00026,242,00045,216,00055,745,00041,287,00037,440,000-14,554,00024,093,000-7,194,00078,000-28,158,000
Earnings
Jan 03, 2025

Profile

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
IPO date
May 27, 2004
Employees
815
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
303,914
-10.28%
338,752
7.13%
316,219
8.66%
Cost of revenue
324,710
338,641
314,978
Unusual Expense (Income)
NOPBT
(20,796)
111
1,241
NOPBT Margin
0.03%
0.39%
Operating Taxes
(7,289)
(1,995)
(3,402)
Tax Rate
NOPAT
(13,507)
2,106
4,643
Net income
(184,349)
251.53%
(52,442)
97.54%
(26,547)
-15.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,171
2,683
BB yield
-0.31%
-0.35%
Debt
Debt current
1,975
1,922
8,783
Long-term debt
7,878
56,450
29,703
Deferred revenue
Other long-term liabilities
12,139
4,569
12,901
Net debt
(66,203)
26,565
9,661
Cash flow
Cash from operating activities
(28,158)
78
(7,194)
CAPEX
(2,518)
(4,352)
(4,297)
Cash from investing activities
123,717
(9,746)
(19,307)
Cash from financing activities
(64,248)
25,420
7,683
FCF
13,130
(9,177)
(13,035)
Balance
Cash
76,056
44,620
28,825
Long term investments
(12,813)
Excess cash
60,860
14,869
13,014
Stockholders' equity
(399,184)
(215,196)
(156,676)
Invested Capital
622,823
667,878
627,099
ROIC
0.33%
0.75%
ROCE
0.02%
0.26%
EV
Common stock shares outstanding
40,181
39,480
39,009
Price
6.31
-33.30%
9.46
-51.81%
19.63
-15.10%
Market cap
253,542
-32.11%
373,484
-51.23%
765,755
-13.62%
EV
187,339
400,049
775,416
EBITDA
6,916
30,984
30,590
EV/EBITDA
27.09
12.91
25.35
Interest
2,702
688
Interest/NOPBT
2,434.23%
55.44%